Contributions
Abstract: EP1824
Type: ePoster
Abstract Category: Therapy - symptomatic - 33 Treatment of specific symptoms
Background: tDCS is a therapeutic approach that applies low amplitude currents (typically 1-4 mA) through scalp electrodes with the goal of altering the resting state of neurons for potential therapeutic benefit. A growing body of evidence indicates that tDCS applied to the left dorsolateral prefrontal cortex (DLPFC) may be beneficial in the treatment of depression, a common comorbidity with multiple sclerosis (MS). The DLPFC is a neurobiological substrate related to both aspects of mood and cognition. We tested mood outcomes in a recently completed randomized sham-controlled and double blinded trial of tDCS in MS participants.
Methods: Participants with MS were recruited to participate in a randomized, sham-controlled trial of tDCS testing remote (at-home) delivery of treatment. Supervised in real time through videoconferencing, participants completed 20 treatment sessions from home over four weeks. Participants were randomly assigned to active (2.0mA left anodal) or sham tDCS using the DLFPC montage. Sessions were administered for 20 minutes during which participants also completed cognitive training exercises each session. Participants completed self-report questionnaires at baseline and study end visits, including the Positive and Negative Affect Schedule or PANAS to provide specific components of mood.
Results: Participants receiving active tDCS (n=14) reported a significant increase in PA and decrease in NA by study end (mean changes of 4.4±6.2, p=0.02 and -5.7±5.9, p=0.003, respectively). Sham-treated participants (n=10) did not show significant change in either positive or negative affect (mean changes of 4.4±6.2 vs -0.6±6.2, p=0.068 and mean changes of -5.7±5.9 vs -2.0±5.0, p=0.111, respectively).
Conclusions: Twenty sessions of tDCS, administered at home using a telerehabilitation protocol, significantly increases positive affect and decreases negative affect in participants with MS. Findings support the role of DLPFC in regulating mood and warrant a clinical trial for the treatment of MS-related depression.
Disclosure:
Michael Shaw has nothing to disclose.
Bryan Dobbs has nothing to disclose.
Natalie Pawlak has nothing to disclose.
William Pau has nothing to disclose.
Leigh Charvet has nothing to disclose.
Abstract: EP1824
Type: ePoster
Abstract Category: Therapy - symptomatic - 33 Treatment of specific symptoms
Background: tDCS is a therapeutic approach that applies low amplitude currents (typically 1-4 mA) through scalp electrodes with the goal of altering the resting state of neurons for potential therapeutic benefit. A growing body of evidence indicates that tDCS applied to the left dorsolateral prefrontal cortex (DLPFC) may be beneficial in the treatment of depression, a common comorbidity with multiple sclerosis (MS). The DLPFC is a neurobiological substrate related to both aspects of mood and cognition. We tested mood outcomes in a recently completed randomized sham-controlled and double blinded trial of tDCS in MS participants.
Methods: Participants with MS were recruited to participate in a randomized, sham-controlled trial of tDCS testing remote (at-home) delivery of treatment. Supervised in real time through videoconferencing, participants completed 20 treatment sessions from home over four weeks. Participants were randomly assigned to active (2.0mA left anodal) or sham tDCS using the DLFPC montage. Sessions were administered for 20 minutes during which participants also completed cognitive training exercises each session. Participants completed self-report questionnaires at baseline and study end visits, including the Positive and Negative Affect Schedule or PANAS to provide specific components of mood.
Results: Participants receiving active tDCS (n=14) reported a significant increase in PA and decrease in NA by study end (mean changes of 4.4±6.2, p=0.02 and -5.7±5.9, p=0.003, respectively). Sham-treated participants (n=10) did not show significant change in either positive or negative affect (mean changes of 4.4±6.2 vs -0.6±6.2, p=0.068 and mean changes of -5.7±5.9 vs -2.0±5.0, p=0.111, respectively).
Conclusions: Twenty sessions of tDCS, administered at home using a telerehabilitation protocol, significantly increases positive affect and decreases negative affect in participants with MS. Findings support the role of DLPFC in regulating mood and warrant a clinical trial for the treatment of MS-related depression.
Disclosure:
Michael Shaw has nothing to disclose.
Bryan Dobbs has nothing to disclose.
Natalie Pawlak has nothing to disclose.
William Pau has nothing to disclose.
Leigh Charvet has nothing to disclose.